NeoGenomics Inc. (NEO)
NASDAQ: NEO
· Real-Time Price · USD
7.99
-0.35 (-4.20%)
At close: Sep 12, 2025, 12:24 PM
-4.20% (1D)
| Bid | 5.94 |
| Market Cap | 203.53M |
| Revenue (ttm) | 689.19M |
| Net Income (ttm) | -104.04M |
| EPS (ttm) | -0.82 |
| PE Ratio (ttm) | -9.74 |
| Forward PE | 41.56 |
| Analyst | Buy |
| Ask | 10.22 |
| Volume | 641,001 |
| Avg. Volume (20D) | 2,536,774 |
| Open | 8.38 |
| Previous Close | 8.34 |
| Day's Range | 7.98 - 8.38 |
| 52-Week Range | 4.72 - 19.11 |
| Beta | 1.61 |
Analyst Forecast
According to 0 analyst ratings, the average rating for NEO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
NeoGenomics Inc. is scheduled to release its earnings on
Nov 4, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago
+21.78%
NeoGenomics shares are trading higher after the co...
Unlock content with
Pro Subscription
1 month ago
-18.73%
NeoGenomics shares are trading lower after the company reported a Q2 revenue miss and cut its FY25 sales guidance below estimates.
2 months ago · businesswire.com
NeoGenomics Announces PanTracer Tissue and PanTracer Tissue + HRD Now Available to Support More Informed and Timely Cancer CareFORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics launched PanTracer™ Tissue, a next-generation solid tumor profiling assay, with the option to add HRD testing.